Echoes of a failure: what lessons can we learn?

Affiliations

¹ Department of Cutaneous Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA. Electronic address: vernon.sondak@moffitt.org.
² Department of Cutaneous Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

Comment

Vernon K Sondak et al. Lancet Oncol. 2019 Aug.

. 2019 Aug;20(8):1037-1039.

doi: 10.1016/S1470-2045(19)30312-2. Epub 2019 Jun 17.

¹ Department of Cutaneous Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA. Electronic address: vernon.sondak@moffitt.org.
² Department of Cutaneous Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.

No abstract available

Comment on

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC. Long GV, et al. Lancet Oncol. 2019 Aug;20(8):1083-1097. doi: 10.1016/S1470-2045(19)30274-8. Epub 2019 Jun 17. Lancet Oncol. 2019. PMID: 31221619 Clinical Trial.